pp-088 Tablets

Indication: Advanced solid tumors and hematologic malignancies harboring wild-type p53, including cancers in which p53 pathway reactivation may overcome therapeutic resistance. Clinical stage: Phase I clinical development, including dose-escalation studies evaluating safety, tolerability, pharmacokinetics, and preliminary antitumor activity. Modality: Small-molecule targeted therapy Mechanism / Target: Next-generation inhibitor of the MDM2–p53 protein–protein interaction designed to stabilize and reactivate p53, inducing apoptosis and cell-cycle arrest in p53-competent tumors. Route / form: Oral formulation Differentiation: Engineered to enhance p53 activation potency with an improved safety and pharmacokinetic profile compared with earlier MDM2 inhibitors; aims to broaden therapeutic applicability and support combination strategies with other anticancer agents.